Redx Pharma plc Notice of Interim Results (1235E)

TIDMREDX

RNS Number : 1235E

Redx Pharma plc

04 May 2017

4 May 2017

AIM: REDX

REDX PHARMA PLC

("Redx" or "the Company")

Notice of Interim Results

Redx Pharma, the research and development company focused on cancer, immunology and infection, announces that its interim results for the six months ended 31(st) March 2017 will be announced on Wednesday 17(th) May 2017.

Dr. Neil Murray, Chief Executive Officer, and Andrew Booth, Interim Finance Director, will host a presentation and conference call for analysts and investors at 12:30pm BST / 7:30am EDT on the day of results at the offices of Consilium Strategic Communications, 41 Lothbury, London, EC2R 7HG. The presentation for the call will be made available on the Company website (www.redxpharma.com) in advance of the call.

For further information, please contact:

 
Redx Pharma Plc 
Neil Murray, Chief Executive Officer         T: +44 1625 
                                                 469 900 
Karl Hård, Head of Investor Relations   T: +44 7491 
 &                                               651 406 
 Corporate Communications 
 
  Cantor Fitzgerald Europe (Nomad & Broker)    T: +44 20 
                                               7894 7000 
Phil Davies/ Michael Reynolds 
 
WG Partners LLP (Joint Broker)                 T: +44 20 
                                               3705 9330 
Claes Spång/ Chris Lee/ David 
 Wilson 
                                               T: +44 20 
  Consilium Strategic Communications           3709 5700 
Amber Fennell/ Matthew Neal/ Melissa 
 Gardiner 
 

About Redx Pharma Plc

Company website: www.redxpharma.com

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, immunology and infection providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a broad portfolio of proprietary drug programs.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORAJMBTMBBMTIR

(END) Dow Jones Newswires

May 04, 2017 02:01 ET (06:01 GMT)